Micar Innovation is a drug discovery engine. Micar Innovation creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions.
Drug discovery operations are built around an experienced team of researchers. Previous accomplishments of Micar Innovation team members led to multiple marketed and clinical-stage drugs in diverse disease areas including neurology, oncology, arthritis. Micar Innovation business model includes “Build-to-Buy” partnerships, where world-class academic researchers are matched with pharmaceutical partners to form new drug discovery programs for the Micar Innovation team to execute upon. New start-up companies are spun-out for translation of these programs into novel therapies, incorporating an exclusive option for a pharmaceutical partner to acquire a spun-out company downstream at pre-set terms. Micar Innovation has now formed multiple companies around discovery programs subject to Build-to-Buy agreements.
- Operations Service
- Own Drug Discovery Programs
- Rare Diseases
Data type used for modelling
- Chemical notations and molecular fingerprints
- EHRs/lab notebooks/databases (structured data mining)
Drug Discovery Strategy
- Structure Based Drug Discovery (SBDD)
- Small molecules
- Biology research (Target identification/validation)
- Data mining / Ontology building
- Lead Discovery
- Preclinical Development